DexCom (DXCM) revenues in the third quarter were 1.34 billion USD (+11.2% y/y), while earnings per share (adjusted) increased by 19.7% y/y to 0.73 USD.

Quarterly results#

The company’s operating income reached 327.20 million USD (+34.9% y/y), while net income decreased by 3.1% y/y to 275.10 million USD. Earnings per share (GAAP) stood at 0.72 USD (+2.9% y/y), and earnings per share (GAAP, basic) remained unchanged compared to the previous year, at 0.73 USD (0.0% y/y).

What management says#

Management emphasized that despite market turbulence, the assessment of the company’s opportunities remains unchanged, and the long-term plan inspires great confidence. According to management, reimbursement in international markets is maintaining a stable level. Management expects a decision regarding reimbursement for patients with diabetes not treated with insulin later this year. Management indicated that the publication of a study in a prestigious medical journal constitutes breakthrough evidence of the effectiveness of the company’s systems, which, according to management, should significantly impact treatment standards. According to management, insurers typically provide equitable access to different systems, as patients, physicians, and employers strive to have a choice.